Drugs / Bertilimumab
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT02226146 | Feb 2016 → Apr 2018 | bullous pemphigoid | Alexion Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT01671956 | Jul 2015 → Aug 2018 | ulcerative colitis | Alexion Pharmaceuticals, Inc. | Terminated | No outcome recorded Stop: Business |
Press releases naming this drug 6 releases
| Date | Issuer | Release |
|---|---|---|
| 2019-12-11 | iCo Therapeutics Inc. | iCo Therapeutics Engages Ora for iCo-008 Ophthalmic Strategy and Pre Phase II FDA Meeting icotherapeutics.com ↗ |
| 2019-11-25 | iCo Therapeutics Inc. | Alexion Pharmaceuticals – iCo’s New Partner for the Development and Commercialization of iCo-008 icotherapeutics.com ↗ |
| 2019-02-19 | iCo Therapeutics Inc. | iCo Therapeutics Inc. Announces Notice of Termination of Sub License for Bertilimumab (iCo-008) icotherapeutics.com ↗ |
| 2011-06-24 | iCo Therapeutics Inc. | iCo Therapeutics Executes Bertilimumab License with Immune Pharmaceuticals icotherapeutics.com ↗ |
| 2010-12-08 | iCo Therapeutics Inc. | iCo Therapeutics Grants License Option for Bertilimumab (iCo-008) Systemic Uses to Immune Pharmaceuticals for US$33 Million Plus Royalties icotherapeutics.com ↗ |
| 2008-03-10 | iCo Therapeutics Inc. | iCo Therapeutics Provides iCo-008 Phase II Clinical Update icotherapeutics.com ↗ |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Bertilimumab | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01671956 ↗ |
| Known as | CAT-213 | ChEMBL registry synonym — accepted as the source's own label CHEMBL2109103 ↗ |
| Known as | ICO-008 | ChEMBL registry synonym — accepted as the source's own label CHEMBL2109103 ↗ |
| Action | Inhibit | “Eotaxin inhibitor” CHEMBL2109103 ↗ |
| Modality | Monoclonal antibody | — CHEMBL2109103 ↗ |
| Route | Intravenous | “administered by IV infusion” NCT01671956 ↗ |
| Target | CCL11 | “Eotaxin inhibitor” CHEMBL2109103 ↗ |